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Abstract
Due to compromised homologous recombination (HR) repair,
BRCA1- and BRCA2-mutated tumours accumulate DNA damage and
genomic rearrangements conducive of tumour progression. To
identify drugs that target specifically BRCA2-deficient cells, we
screened a chemical library containing compounds in clinical use.
The top hit was chlorambucil, a bifunctional alkylating agent used
for the treatment of chronic lymphocytic leukaemia (CLL). We
establish that chlorambucil is specifically toxic to BRCA1/2-defi-
cient cells, including olaparib-resistant and cisplatin-resistant
ones, suggesting the potential clinical use of chlorambucil against
disease which has become resistant to these drugs. Additionally,
chlorambucil eradicates BRCA2-deficient xenografts and inhibits
growth of olaparib-resistant patient-derived tumour xenografts
(PDTXs). We demonstrate that chlorambucil inflicts replication-
associated DNA double-strand breaks (DSBs), similarly to cisplatin,
and we identify ATR, FANCD2 and the SNM1A nuclease as determi-
nants of sensitivity to both drugs. Importantly, chlorambucil is
substantially less toxic to normal cells and tissues in vitro and
in vivo relative to cisplatin. Because chlorambucil and cisplatin are
equally effective inhibitors of BRCA2-compromised tumours, our
results indicate that chlorambucil has a higher therapeutic index
than cisplatin in targeting BRCA-deficient tumours.
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Introduction
BRCA1 and BRCA2 germline mutations have been associated with
approximately 25% of the familial cases of breast and ovarian
cancer (Futreal et al, 1994; Miki et al, 1994; Wooster et al, 1995);
therefore, BRCA1 and BRCA2 represent classical tumour suppressor
genes (Lord & Ashworth, 2016). In addition, somatic BRCA1 and
BRCA2 mutations, as well as their epigenetic inactivation, have been
unravelled in a significant proportion of the sporadic cancers, by
recent comprehensive genome sequencing studies (Cancer Genome
Atlas Research Network, 2011; Cancer Genome Atlas Network,
2012; Curtis et al, 2012; Ali et al, 2014; Pereira et al, 2016). Thus,
the subset of patients affected by BRCA1/2 mutations appears to be
greater than initially anticipated.
BRCA1 and BRCA2 play essential roles in DNA replication and
DSB repair (Michl et al, 2016). Both factors promote HR, a DNA
repair pathway active during S/G2 phases of the cell cycle, which
also provides a mechanism for the re-start of stalled replication
forks. Consequently, BRCA1 or BRCA2 abrogation confers exquisite
sensitivity to DNA damage-inducing drugs, in particular those
inflicting cytotoxic DNA crosslinks (i.e. platinum drugs and DNA
alkylators), which interfere with DNA replication.
Sensitivity of BRCA1/2-mutated tumours to platinum compounds
has been validated in multiple pre-clinical and clinical studies
(Byrski et al, 2009, 2010; Silver et al, 2010; Tutt et al, 2018).
Cisplatin and its derivatives are widely used chemotherapeutic
drugs, which inflict complex DNA lesions in the form of intra- and
inter-strand crosslinks (ICLs; Deans & West, 2011). Similar lesions
are induced by DNA-alkylating agents (Fu et al, 2012), which
include mono-functional (e.g. mitomycin C, nimustine) or bifunc-
tional alkylators (e.g. chlorambucil, cyclophosphamide, melphalan),
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some showing specific toxicity against BRCA1/2-deficient cells and
tumours (Evers et al, 2010; Vollebergh et al, 2014; Pajic et al,
2017). Interestingly, cisplatin induces primarily intrastrand cross-
links (Jamieson & Lippard, 1999), whilst bifunctional alkylators
cause mainly ICLs, which represent the most potent type of cyto-
toxic DNA lesion (McHugh et al, 2001). Although alkylating agents
display similar selectivity to cisplatin in targeting BRCA1/2-deficien-
cies, they have largely been abandoned for clinical use in breast and
ovarian cancers, due to early sub-optimal results in non-stratified
patient populations (Williams et al, 1985).
Small molecule inhibitors of poly(ADP-ribose) polymerase
(PARP) are currently at the forefront of clinical research for the
treatment of BRCA-compromised breast, ovarian and prostate
tumours (Mateo et al, 2015; Mirza et al, 2016; Robson et al, 2017;
Litton et al, 2018). PARP inhibitors induce DNA damage indirectly
(Lord & Ashworth, 2017) by immobilising PARP enzymes to DNA
ends and suppressing their ability to PARylate various substrates
(Murai et al, 2012; Pascal & Ellenberger, 2015).
In spite of the fact that platinum drugs and PARP inhibitors show
initially good responses in the clinic, most patients acquire resis-
tance to these drugs (Rottenberg et al, 2007; Sakai et al, 2008;
Shafee et al, 2008; Tutt et al, 2010; Norquist et al, 2011; Ter Brugge
et al, 2016). Thus, there is a clear necessity for identifying new
drugs or drug combinations that can target BRCA1/2-deficient cells
and tumours. Here, we report the screen of a chemical library
containing 1,280 drugs approved for clinical use by the US Food and
Drug Administration (FDA). The highest scoring hit in our screen
was chlorambucil, a bifunctional alkylator routinely used in
chemotherapeutic regimens against CLL (Goede et al, 2014; Jain &
O’Brien, 2015). We demonstrate that chlorambucil has high selec-
tive toxicity against human cells and xenograft tumours with
compromised BRCA1/2 function. Mechanistically, chlorambucil acts
by inducing replication stress and DSBs in actively replicating cells.
Although similar to cisplatin in targeting BRCA-deficient tumours,
chlorambucil shows substantially lower toxicity to normal cells and
tissues. Our results suggest that the clinical use of chlorambucil
in the BRCA1/2-deficient subset of cancer patients should be
re-evaluated.
Results
Pharmacological screen for drugs that selectively eliminate
BRCA2-deficient cells
In order to identify drugs in clinical use that can target specifically
BRCA2-deficient cells, we performed a viability screen using the
Prestwick chemical library (http://www.prestwickchemical.com/lib
raries-screening-lib-pcl.html) containing 1,280 FDA-approved drugs.
Since all drugs are suitable for human testing, any compounds
identified in this screen could rapidly be repurposed for the treat-
ment of BRCA1/2-mutated patients. We conducted two independent
screens, each in triplicate, at drug concentration of 5 lM
(Dataset EV1, Appendix Fig S1) using hamster BRCA2-
deficient VC8 cells and control BRCA2-complemented cells (Kraak-
man-van der Zwet et al, 2002). We demonstrated previously (Chai-
kuad et al, 2014; Zimmer et al, 2016) that these BRCA2-deficient
cells are hypersensitive to PARP inhibitors, ERK1/2 inhibitors and
pyridostatin, when compared to BRCA2-proficient counterparts. A
similar chemical library screen aiming to identify drugs that target
BRCA2-deficiency was previously performed (Evers et al, 2010)
using Brca2/ mouse mammary tumour-derived cell lines and the
LO-PAC1280 Sigma library of pharmacologically active compounds
(Dataset EV1). The chemical composition of this library was dif-
ferent from that of the Prestwick library used here, with the two
libraries having approximately 25% compounds in common.
Among the top scoring hits in our Prestwick library screens
(Dataset EV1, Appendix Fig S1), we identified chlorambucil, a
bifunctional alkylating agent used in the past for the treatment of
breast and ovarian cancer (Williams et al, 1985; Senn et al, 1997),
irinotecan, a topoisomerase I inhibitor in use for the treatment of
cancer patients with BRCA1 mutations (Kennedy et al, 2004), and
disulfiram, an aldehyde dehydrogenase inhibitor used in the clinic
as an alcohol deterrent. Our group has recently characterised disulfi-
ram as an agent specifically toxic to BRCA1/2-deficient cells and
tumours, with significant therapeutic potential (Tacconi et al,
2017).
Given that our screens were conducted in hamster cells, we vali-
dated chlorambucil and irinotecan in BRCA2-deficient human cells.
Human colorectal adenocarcinoma BRCA2/ DLD1 cells (Zimmer
et al, 2016; Fig 1A) were hypersensitive to both drugs, when
compared with BRCA2+/+ DLD1 cells. Olaparib and cisplatin were
used as controls for selective targeting of BRCA2-deficient cells.
Moreover, spheroid cultures established from BRCA2/ DLD1 cells
recapitulated the chlorambucil sensitivity observed in 2D cultures
(Fig 1B).
Chlorambucil is toxic to BRCA1-deficient tumour cells, including
those that acquired olaparib resistance
To address the efficacy of chlorambucil against other HR-deficient
cells, we assessed the response to this drug in BRCA1-deficient
human cells. RPE1 cells immortalised by hTERT overexpression and
TP53 knockout, which carry a BRCA1 CRISPR/Cas9-mediated dele-
tion (Zimmermann et al, 2018), were hypersensitive to chlorambu-
cil, as well as to olaparib and cisplatin used as controls (Fig 2A).
Moreover, we tested chlorambucil in cellular models in which
BRCA1 gene inactivation is associated with olaparib resistance.
Olaparib sensitivity characteristic of Brca1-deleted mouse mammary
tumour-derived cells is abrogated upon loss of 53BP1 (Fig 2B;
Bouwman et al, 2010; Tacconi et al, 2017). Nevertheless, these cells
remained hypersensitive to cisplatin and chlorambucil. Notably,
Brca1/53bp1/ cells were more sensitive to cisplatin than
Brca1/ cells. A similar trend was previously reported in mouse
embryonic fibroblasts (Bunting et al, 2012), suggesting that BRCA1/
53BP1-deficient, olaparib-resistant tumours may be also more
responsive to cisplatin in the clinic. This is indeed the case as
demonstrated by a recent clinical trial in which patients with
BRCA1/2 mutated, PARP inhibitor-resistant ovarian cancers showed
a robust response to platinum-based therapies (Ang et al, 2013).
To generate a second model of olaparib resistance, we inacti-
vated REV7 using two different shRNAs in Brca1-deleted mouse
cells, as previously described (Xu et al, 2015). Cells lacking both
REV7 and BRCA1 were less sensitive to olaparib than BRCA1-
deficient; however, they were effectively eliminated by cisplatin and
chlorambucil treatments (Fig 2C). Thus, chlorambucil, similarly to
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cisplatin, can eliminate BRCA1-deficient cells that developed PARP
inhibitor resistance via 53BP1 or REV7 inactivation.
Cisplatin-resistant BRCA2-deficient cells derived from human
tumours are targeted by chlorambucil
To further investigate the therapeutic potential of chlorambucil, we
tested its effect in cell lines established from BRCA2-compromised
human tumours. Capan-1 cells derived from a pancreatic adenocar-
cinoma carry a C-terminal BRCA2 truncation, which impairs RAD51
nuclear localisation (Chen et al, 1998). Capan-1 cells showed signifi-
cantly higher sensitivity to chlorambucil, as well as to cisplatin and
olaparib, when compared to MIA PaCa-2 pancreatic cancer cells
with normal BRCA2 expression (Fig 3A).
As a second tumour-derived model, we used PEO1 cells estab-
lished from a human ovarian tumour carrying a N-terminal BRCA2
truncation, which abrogates HR repair. C4-2 cells, in which wild-
type BRCA2 was restored by treatment with cisplatin (Sakai et al,
2009), were used as a control. Viability assays demonstrated that
PEO1 cells were hypersensitive to chlorambucil, in contrast to C4-2
cells (Fig 3B). Notably, PEO1 cells, as well as other human cell lines
lacking BRCA1 or BRCA2 (DLD1 BRCA2/, HCT116 BRCA2/ and
RPE1 BRCA1/), showed sensitivity to melphalan, another bifunc-
tional alkylator (Appendix Fig S2). These results support the efficacy
of other bifunctional alkylators against BRCA1/2-deficient cells, in
agreement with previous studies (Evers et al, 2010).
Loss of the chromatin remodelling factor CHD4 confers resistance
to cisplatin in BRCA2-deficient PEO1 cells, through unknown, HR-
independent mechanisms that confer DNA damage tolerance (Guil-
lemette et al, 2015). We recapitulated this observation by inhibiting
CHD4 expression in PEO1 BRCA2-deficient cells (Fig 3C). Lentiviral
shRNA-mediated CHD4 depletion increased resistance of PEO1 cells
to cisplatin, whilst it had no effect on the cisplatin response of
BRCA2-proficient C4-2 cells. Importantly, chlorambucil effectively
eliminated both cisplatin-sensitive and cisplatin-resistant BRCA2-
deficient PEO1 cells. These results suggest a potential clinical use
for chlorambucil in targeting BRCA2-deficient tumours which
acquired cisplatin resistance.
Chlorambucil induces replication stress and DNA damage
accumulation in BRCA2-deficient cells
Alkylating agents can inflict DNA lesions in the form of intra-
and inter-strand DNA crosslinks, with a bias towards the latter
(Deans & West, 2011). HR repair is an obligatory step in ICL
resolution. In cells with compromised HR repair, ICLs interfere
with DNA replication, leading to DSB accumulation and cell death
(Michl et al, 2016). We therefore addressed the possibility that
chlorambucil toxicity to BRCA2-deficient cells is due to ICL-
inflicted DNA replication and DSB repair defects. The response of
BRCA2-proficient and BRCA2-deficient DLD1 cells to chlorambucil
was evaluated using time course experiments and immunoblotting
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Figure 1. Chlorambucil sensitivity of BRCA2-deficient human cells and spheroids.
A Dose-dependent viability assays of BRCA2-proficient (+BRCA2) or BRCA2-deficient (BRCA2) human DLD1 cells treated with drugs at the indicated concentrations for
6 days.
B Human spheroids established from BRCA2-proficient (+BRCA2) or BRCA2-deficient (BRCA2) DLD1 cells were incubated with 1.25 µM olaparib or 0.5 µM chlorambucil
over the indicated period of time.
Data information: (A, B) Graphs represent average values obtained from three independent experiments, each performed in triplicate. Error bars represent SEM.
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Figure 2. Chlorambucil sensitivity of BRCA1-deficient human and mouse cells, including those that have acquired olaparib resistance.
A Dose-dependent viability assays of BRCA1-proficient (+BRCA1) or BRCA2-deficient (BRCA1) human RPE1-hTERT and TP53-deleted cells treated with drugs at the
indicated concentrations for 6 days.
B, C Dose-dependent viability assays of Brca1+/+ and Brca1/ mouse mammary tumour-derived cell lines treated with drugs at the indicated concentrations for 6 days.
Data information: (A–C) Graphs represent average values obtained from three independent experiments, each performed in triplicate. Error bars represent SEM.
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Figure 3. Chlorambucil sensitivity of BRCA2-deficient human tumour-derived cell lines, including those that have acquired cisplatin resistance.
A Dose-dependent viability assays of BRCA2-deficient (Capan-1) or BRCA2-proficient (MIA PaCa-2) human pancreatic carcinoma-derived cells treated with drugs at the
indicated concentrations for 6 days.
B Dose-dependent viability assays of BRCA2-deficient (PEO1) or BRCA2-proficient (C4-2) human ovarian tumour-derived cells treated with drugs at the indicated
concentrations for 6 days.
C BRCA2-deficient (PEO1) or BRCA2-proficient (C4-2) human ovarian tumour-derived cells were infected with lentiviruses expressing control or CHD4 shRNAs, followed
by selection with puromycin for 72 h. Dose-dependent viability assays were performed on cells treated with drugs at the indicated concentrations for 6 days.
Data information: (A, B) Graphs represent average values obtained from three independent experiments, each performed in triplicate. Error bars represent SEM. (C) Error
bars represent SEM of three technical replicates.
Source data are available online for this figure.
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for checkpoint activation markers (Fig 4A). RPA phosphorylation
at Ser33, a marker for ATR activation and replication stress
(Zeman & Cimprich, 2014), was induced in BRCA2-proficient cells
following exposure to 1 lM chlorambucil for 48 h. In contrast,
BRCA2-deficient cells, with intrinsic defects in replication fork
progression and stability (Zimmer et al, 2016), showed detectable
levels of RPA Ser33 phosphorylation even in the absence of any
treatment (0 h), and these were markedly increased upon incuba-
tion with 1 lM chlorambucil from 16 h onwards. BRCA2-deficient
cells also showed elevated levels of KAP1 Ser824 phosphoryla-
tion, a signature of ATM-dependent checkpoint activation and
DNA damage accumulation. Phosphorylated KAP1 was detected
from 24 h of treatment with chlorambucil in BRCA2-deficient
cells. As RPA phosphorylation occurs earlier (16 h), this suggests
that replication stress may precede DSB formation in response to
chlorambucil. Cleaved PARP, an apoptosis marker, was induced
only in cells lacking BRCA2. PARP cleavage was detectable from
16 h onwards, similarly to Ser33 RPA phosphorylation, supporting
the concept that replication stress underlies chlorambucil toxicity
to BRCA2-deficient cells.
ATM activation occurs in response to DSB accumulation
and leads to cytotoxicity. Therefore, we next quantified the
frequency of DSBs and chromosome aberrations in BRCA2+/+
and BRCA2/ cells upon treatment with 1 lM cisplatin or 1 lM
chlorambucil for 72 h (Fig 4B). This concentration was chosen
for both drugs because it has the least toxic effects against
BRCA2-proficient cells in viability assays (Fig 1A), whilst it
induced apoptosis, measured by PARP cleavage (Fig 4A and
Appendix Fig S3A), in BRCA2-deficient cells. Both treatments
inflicted a significant level of DSBs and chromosome aberrations
in BRCA2-deficient cells (Fig 4B), with cisplatin inducing more
lesions than chlorambucil. This reflects the higher cytotoxicity of
cisplatin (Fig 1A), as only 10% of BRCA2/ cells remain viable
upon exposure to 1 lM cisplatin, in contrast to 30% of the cells
treated with 1 lM chlorambucil. More than 90% of BRCA2+/+
cells are viable after treatment with 1 lM of either drug. DNA
damage accumulation leads to checkpoint activation which alters
cell cycle progression. Consistent with this, we observed that a
high percentage of cisplatin-treated cells arrested in G2/M
(Fig 4C). In contrast, chlorambucil treatment did not cause a
significant G2/M arrest, in spite of inducing DNA damage associ-
ated with KAP1 phosphorylation (Fig 4A).
Molecular determinants of sensitivity to chlorambucil
and cisplatin
Elucidating which pathways are involved in the repair of chlo-
rambucil- and cisplatin-induced DNA lesions is essential for
understanding the mechanism of action of these drugs. This is
particularly important for cancer chemotherapy, as resistance is
often associated with enhanced DNA repair. On the other hand,
defining novel vulnerabilities to chemotherapeutic drugs may
provide means to sensitise resistant tumours through novel
combination therapies more active in the clinic. We therefore
used siRNA depletion in human RPE1 cells to identify DNA
damage response factors whose inactivation sensitises cells to
chlorambucil and/or cisplatin. Both drugs induce Ser33 RPA
phosphorylation, indicative of replication stress and ATR
activation (Fig 4A and Appendix Fig S3A). We thus depleted ATR
using siRNA and observed that cells lacking ATR are hypersensi-
tive to both drugs, supporting a key role for this checkpoint
kinase in the cellular responses to chlorambucil and cisplatin
(Fig 4D). This result is consistent with a recent study, which
showed that depletion of CHK1, an ATR phosphorylation target,
sensitises cells to chlorambucil and cisplatin (Bruno et al, 2017).
ATR orchestrates cell responses to replication stress, including
activation of the Fanconi anaemia (FA) pathway of ICL recognition
and repair (Zhang & Walter, 2014). Given the ability of cisplatin and
chlorambucil to induce ICLs, it was perhaps not surprising that
abrogating FANCD2, a central FA protein, sensitised human cells to
both agents (Fig 4E). ATR regulates FA by promoting FANCD2
mono-ubiquitylation (Andreassen et al, 2004), which, in turn,
recruits to the chromatin nucleases required for ICL incision and
unhooking. The XPF-ERCC1 nuclease makes the first incision at ICL
sites. SNM1A nuclease is then recruited to those structures that
resemble stalled forks, to complete ICL unhooking in concert with
XPF-ERCC1 (Abdullah et al, 2017). Hypersensitivity of ERCC1 and
XPF mutant cells to crosslinking anti-cancer drugs is well docu-
mented (McHugh et al, 2001); however, whether SNM1A-deficient
cells recapitulate this sensitivity is unknown. We found that
SMN1A-depleted human cells were also sensitive to cisplatin and
chlorambucil (Fig 4E), indicating an important role for this nuclease
in ICL repair.
Whilst XPF-ERCC1 is a known downstream effector of the FA
pathway, whether SNM1A functions in FA-dependent manner is
unknown. To address a possible cooperation between FA and
SNM1A in ICL repair, we co-depleted FANCD2 and SNM1A and
evaluated the response to cisplatin and chlorambucil. We found that
inactivation of both factors did not further sensitise cells compared
to FANCD2 depletion alone (Fig 4E). Control experiments
performed in cells depleted of XPF and/or FANCD2 using siRNAs
showed a similar pattern (Appendix Fig S4). These results demon-
strate the concerted action of SNM1A, XPF and FANCD2 upon ICL
induction and place for the first time the SNM1A nuclease within
the FA pathway of ICL repair.
The anti-tumoral effect of chlorambucil against BRCA2-deficient
xenografts is similar to cisplatin
Chlorambucil inhibited specifically the growth of BRCA2-deficient
spheroids established from DLD1 cells (Fig 1B), indicative of its
potential use in a tumour setting. Thus, we used BRCA2+/+ and
BRCA2/ DLD1 cells to generate xenograft tumours in mice (Fig 5A
and B). Chlorambucil had no effect on the growth of BRCA2-profi-
cient tumours (Fig 5A), but it caused a striking reduction in BRCA2-
deficient tumour growth (Fig 5B). When the drug was administered
intraperitoneally at doses of 3 mg/kg daily for 10 days (with a 2-day
break after day 5), we observed tumour eradication in all animals
within 21 days from treatment initiation.
Chlorambucil doses approved for CLL patient treatment are 0.2–
1.6 mg/kg daily. In our mouse experiments, we used the maximum
tolerated dose of 3 mg/kg daily (Weisburger et al, 1975; Grosse
et al, 2009), which corresponds to 0.25 mg/kg daily patient dose,
calculated using FDA conversion guidelines from mouse to human
(http://www.fda.gov/downloads/Drugs/. . ./Guidances/UCM078932.
pdf), and it is therefore clinically relevant. We further reduced the
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dose administered in mice and observed that BRCA2-deficient
tumours were also eliminated even at doses of 1 mg/kg daily chlo-
rambucil. However, a 0.3 mg/kg daily dose was ineffective
(Appendix Fig S5). Thus, chlorambucil is active against BRCA2-defi-
cient tumours even at doses lower than the equivalent doses used in
the clinic.
To further investigate the therapeutic potential of chlorambucil,
we used ex vivo cultures of patient-derived tumour xenograft cells
(PDTCs; Fig 5C). These recapitulate not only tumour heterogeneity,
but also tumour vulnerability to specific drugs (Bruna et al, 2016).
Chlorambucil was selectively toxic to PDTCs lacking normal BRCA1
expression (STG201, VHIO179; http://caldaslab.cruk.cam.ac.uk/bca
pe/) and had a small effect on BRCA1-proficient ones (AB521).
Importantly, VHIO179, a tumour carrying BRCA1 germline trunca-
tion, is resistant to treatment with PARP inhibitors due to a MAD2L2
(REV7) inactivating mutation (Bruna et al, 2016; Cruz et al, 2018).
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Figure 4. DNA damage responses to chlorambucil and cisplatin in human cells.
A BRCA2-proficient (+BRCA2) or BRCA2-deficient (BRCA2) human DLD1 cells were incubated with 1 µM chlorambucil (Chl). Whole-cell extracts prepared at the
indicated time points during treatment were immunoblotted as shown. GAPDH was used as a loading control.
B Quantification of chromosome aberrations and chromatid/chromosome break frequencies in BRCA2-proficient (+BRCA2) or BRCA2-deficient (BRCA2) human DLD1
cells incubated with 1 lM chlorambucil or 1 µM cisplatin for 72 h. Data were obtained from three independent experiments and normalised to untreated controls.
A minimum of 60 Giemsa-stained metaphases were analysed for each sample. Cis, cisplatin; Chl, chlorambucil.
C Quantification of G2/M cell frequency relative to solvent control, using FACS analyses of cells incubated with 1 lM chlorambucil or 1 µM cisplatin for 48 h. Cis,
cisplatin; Chl, chlorambucil.
D, E Human H1299 cells were treated with control (CTR) or indicated siRNAs 2 days before drugs were added to the media for dose-dependent viability assays. Cell
extracts prepared at the time of drug addition were immunoblotted as indicated. SMC1 was used as a loading control.
Data information: (B) Whiskers indicate 10–90 percentile, and red bars indicate mean frequencies of breaks. P-values were calculated using the Mann–Whitney test.
****P < 0.0001. (C) Error bars represent SEM of three independent experiments. P-values were calculated using an unpaired two-tailed t-test. **P ≤ 0.01. NS, P > 0.5.
(D, E) Graphs represent average values obtained from three independent experiments, each performed in triplicate. Error bars represent SEM. Exact P-values are included
in Appendix Table S1.
Source data are available online for this figure.
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PDTCs derived from this tumour were sensitive to chlorambucil,
which supports our results obtained with the Brca1-deleted mouse
mammary tumour-derived cells, upon REV7 depletion using shRNAs
(Fig 2C). These results strengthened the therapeutic potential of
chlorambucil for targeting BRCA-deficient human tumours that
acquired resistance to olaparib.
We next determined chlorambucil anti-tumour activity using
paired BRCA2+/+ and BRCA2/ HCT116 colon carcinoma cell
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Figure 5. Chlorambucil impairs growth of BRCA2-deficient tumours and PDTXs.
A, B Nude mice (nu/nu) were injected subcutaneously with 5 × 106 human DLD1 cells, BRCA2-proficient (A) or BRCA2-deficient (B). Tumour-bearing mice were treated
with 3 mg/kg daily chlorambucil administered intraperitoneally (i.p.) for a total of 10 days. Tumour weight was determined on the indicated days after initiation of
the treatment.
C PDTCs derived from breast cancer samples as previously described (Bruna et al, 2016) were treated with chlorambucil at the indicated doses. Cell survival is
represented relative to DMSO control. AB521, ER-negative tumour, no BRCA1 alteration; STG201, tumour with BRCA1 promoter methylation and loss of BRCA1
expression; VHIO179, tumour with BRCA1 germline mutation and MAD2L2 inactivating mutation (olaparib-resistant); http://caldaslab.cruk.cam.ac.uk/bcape/.
D CB17/SCID mice were injected intramuscularly with 5 × 106 human BRCA2-deficient HCT116 cells. Tumour-bearing mice were treated on the indicated days with
chlorambucil or cisplatin administered intraperitoneally (i.p.), or talazoparib administered orally (o.s.) Tumour volume was measured on the indicated days after
treatment initiation and was expressed relative to tumour volume at the beginning of treatment (day 1). Scale bar, 40 µm.
Data information: (A, B) Each experimental group included n = 4 mice. Error bars represent SEM. (C) Error bars represent SEM of two independent experiments
performed in technical triplicates. (D) Each experimental group included n = 5 mice. Error bars represent SEM. Tumour sections were assessed at the end of each
treatment using immunohistochemistry of cH2AX staining. P-values were calculated using an unpaired two-tailed t-test. ****P < 0.0001; ***P < 0.001. Exact P-values
are included in Appendix Table S1.
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lines, generated in one of our laboratories (Xu et al, 2014). BRCA2/
HCT116 cells showed hypersensitivity to cisplatin and chlorambucil
in vitro (Appendix Fig S6A). Xenograft tumours were subsequently
established from BRCA2+/+ and BRCA2/ HCT116 cells and
assessed for their response to chlorambucil, cisplatin and talazoparib
(Appendix Fig S6B). Chlorambucil had no effect on the BRCA2-profi-
cient tumours, but it inhibited the growth of BRCA2-deficient ones.
We further used BRCA2/ HCT116-derived tumours to compare the
anti-tumoral effects of cisplatin, chlorambucil and the PARP inhibitor
talazoparib (Fig 5D). Treatment with each of the three drugs showed
tumour growth inhibition at the nadir of the effect of 89, 89 and 85%,
respectively (Table 1), with a progression-free survival of 19, 21 and
24 days, suggesting similar anti-tumoral activities against BRCA2-
defective tumours. Importantly, the three drugs inflicted comparable
levels of DNA damage evaluated by immunohistochemical staining
with an anti-cH2AX antibody (Fig 5D).
Higher cisplatin toxicity in vitro and in vivo compared
to chlorambucil
Our cell viability assays (Fig 1A) indicated that cisplatin is relatively
more toxic to BRCA2+/+ DLD1 cells than chlorambucil, whilst both
drugs induced cleaved PARP expression in BRCA2/ DLD1 cells
(Fig 4A and Appendix Fig S3A). To further explore the differential
toxicity of the two drugs to BRCA2-proficient cells, we treated MRC5
primary-like cells with cisplatin or chlorambucil for up to 72 h
(Appendix Fig S3B). Under these conditions, we observed a higher
accumulation of the apoptotic marker in response to cisplatin than
chlorambucil treatment, supporting the notion that cisplatin is more
toxic than chlorambucil to non-tumour cells.
MRC5 cells have intact p53 pathway (Carlos et al, 2013), which
may account for the exquisite toxicity of cisplatin and chlorambucil
to these cells. p53 is a key determinant of cell sensitivity to plat-
inum-based drugs (Kelland, 2007). We did not succeed in abrogat-
ing p53 expression in MRC5 cells, and instead, we used RPE1 cells
in which TP53 was deleted using the CRISPR/Cas9 system to
address the role of p53 in the cellular response to chlorambucil.
Functional p53 sensitised cells to cisplatin, as well as to chlorambu-
cil (Appendix Fig S3C), whilst its abrogation promoted resistance.
This supports the notion that p53-dependent responses mediate the
cytotoxicity of these drugs.
The observation that cisplatin is more toxic than chlorambucil
in vitro prompted us to assess the relative toxicities of the two drugs
in vivo. We therefore treated wild-type mice with the maximum
tolerated doses of each drug and evaluated apoptosis in vivo using
single-photon emission computed tomography (SPECT) imaging of
the apoptosis imaging marker 99mTc-Duramycin (Palmieri et al,
2018; Fig 6A). SPECT image quantification demonstrated significant
accumulation of 99mTc-Duramycin in the heart, blood and lungs of
cisplatin-treated mice. Apoptosis levels in the organs of chlorambu-
cil-treated mice were similar to the control, solvent-treated group.
We furthermore used lung and heart from treated mice for immuno-
histochemistry staining with cH2AX antibody (Fig 6B). Consistent
with the biodistribution of the apoptosis tracer 99mTc-Duramycin,
we observed significantly higher cH2AX levels in the heart and
lungs of cisplatin-treated mice, relative to the chlorambucil-treated
ones. DNA lesion accumulation, visualised with cH2AX staining,
was also detected in the organs from chlorambucil-treated animals,
indicating that both drugs inflict DNA damage in vivo. However,
cisplatin induced more pronounced and more deleterious lesions
than chlorambucil. Given the higher toxicity of cisplatin to normal
tissues (Fig 6A and B) and the similar anti-tumour effect of the two
drugs (Fig 5C), we propose that chlorambucil represents a potential
alternative to cisplatin for the treatment of BRCA-deficient tumours.
Discussion
In this study, we report identification of the bifunctional alkylator
chlorambucil in a chemical library screen for drugs with specific
toxicity against BRCA2-deficient cells. DNA alkylators, including
chlorambucil, melphalan and nimustine, were also isolated in a
previous screen and shown to be active in vivo against allografted
BRCA2-deleted mouse tumours (Evers et al, 2010). Subsequent
studies have substantiated the potential of nimustine in targeting
BRCA-deficient tumours (Pajic et al, 2017).
Our work demonstrates the specific toxicity of chlorambucil to
BRCA1/2-deficient human cells and xenograft tumours. Importantly,
BRCA1/2-deficient cells with acquired resistance to olaparib or
cisplatin show sensitivity to chlorambucil, suggesting its therapeutic
potential against this difficult to treat tumour subset. Together with
chlorambucil being non-toxic to normal cells and tissues (see
Table 1. In vivo anti-tumour efficacy of chlorambucil, PARP inhibitor talazoparib and cisplatin on HCT116 BRCA2-deficient xenografts.
Treatment
Tumour volume
inhibition
(average, %)
Tumour
regression
(% mice)
Tumour
relapse
(% mice)
Median
progression-free
survival (days; range)
Body weight
loss (average, %) Deaths (% mice)
Chlorambucil 89 100 100 21 (19–25) 1 0
Talazoparib 89 100 100 24 (20–24) 3 0
Cisplatin 85 100 100 19 (18–20) 7 0
Tumours were allowed to grow to 250 mm3 before initiation of treatment. Mice were treated with chlorambucil (i.p.; 3 mg/kg/day) or talazoparib (p.o.; 0.33 mg/
kg/day) for five consecutive days, followed by 2-day break and 5 more days of treatment. Cisplatin (i.p.; 3.3 mg/kg/day) was administered for three consecutive
days, followed by 4-day break and 3 more days of treatment. Each experimental group included n = 5 mice. Tumour volume inhibition was calculated at the
nadir of the effect using the formula: (1-tumour volume in treated mice/tumour volume in untreated mice) × 100 and expressed as average for n = 5 mice in
each group. Tumour regression was defined as percentage of mice in which reduction of tumour volume, after the initiation of treatment, was maintained for at
least 2 weeks. Tumour relapse was defined as percentage of mice in which tumour regrowth was observed after tumour regression. Median progression-free
survival was defined as duration (days) of tumour regression. Body weight loss is reported as weight at the end of treatment relative to the first day of treatment
(%), as average for n = 5 mice in each group.
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below), these results support chlorambucil re-evaluation in cancer
patients with BRCA mutations.
Chlorambucil was used in the treatment of breast and ovarian
cancer until the late 1970s (Barker & Wiltshaw, 1981; Williams et al,
1985; Senn et al, 1997). These early studies did not show a signifi-
cant benefit of chlorambucil, possibly because its effect was
obscured by the lack of molecular markers (e.g. BRCA1/2 status). In
some clinical trials, addition of cisplatin to chlorambucil treatment
was beneficial (Barker & Wiltshaw, 1981). Although the response to
regimens that included cisplatin was initially superior to chlorambu-
cil alone, the overall patient survival was not improved (Williams
et al, 1985). Nevertheless, chlorambucil-based therapies for breast
and ovarian cancer were abandoned, as cisplatin was approved for
broader clinical use and became the leading anti-cancer drug and
first-line treatment for various malignancies.
A major problem associated with cisplatin chemotherapy is the
emergence of drug resistance (Norquist et al, 2011). Proposed resis-
tance mechanisms include insufficient drug access to DNA, enhanced
DNA repair and apoptotic pathways failure (Siddik, 2003).
Chlorambucil resistance in CLL patients has also been documented
(Panasci et al, 2001; Norgaard et al, 2004), although not to a similar
extent as cisplatin resistance. For both drugs, clinical evidence for a
unique resistance mechanism is lacking due to the multifaceted
response to these drugs in patients. Clearly, both drugs induce ICLs
and DSBs; however, the mechanism linking it to apoptosis has not
been elucidated. TP53 mutations known to increase cell tolerance to
DNA damage and limit apoptosis can be reliably correlated with
cisplatin resistance (Siddik, 2003). We show here that this is also the
case for chlorambucil resistance, as indicated by our viability assays
using isogenic p53 wild-type and p53-deleted RPE-1 cells.
An important result reported here is that chlorambucil is toxic
to cisplatin-resistant BRCA2-deficient cancer cells. Although the
mechanism remains to be further elucidated, this may be
explained by the fact that the two drugs inflict distinct DNA
lesions (chlorambucil induces primarily inter- and cisplatin primar-
ily intrastrand crosslinks) which activate distinct DNA damage
response pathways, especially in BRCA-deficient cells with
compromised HR repair.
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Figure 6. Chlorambucil vs. cisplatin in vitro and in vivo toxicity.
A Wild-type Balb/c mice were injected intraperitoneally with solvent (daily) or 3 mg/kg chlorambucil (daily for 5 days) or 3.3 mg/kg cisplatin (daily for 3 days). Uptake of
the apoptosis tracer 99mTc-Duramycin 2 h after intravenous injection was quantified in selected organs using SPECT imaging in the indicated organs. Representative
maximum intensity partial projections showing tracer distribution are shown.
B Immunohistochemical analyses of cH2AX staining in organs from mice treated as in (A). Scale bar, 25 µm.
Data information: (A) Each experimental group included n = 5 mice. Error bars represent SEM. P-values were calculated using one-way ANOVA followed by Tukey’s
multiple comparisons test. ****P < 0.0001; *P < 0.05. (B) Organs from n = 3 mice were analysed for each treatment. Error bars represent SD. P-values were calculated
using one-way ANOVA followed by Tukey’s multiple comparisons test. ****P < 0.0001; *P < 0.05. Exact P-values are included in Appendix Table S1.
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Since cases of cisplatin and chlorambucil resistance (Panasci
et al, 2001; Norgaard et al, 2004; Norquist et al, 2011) in tumours
are documented, it is important to identify which DNA damage
repair defects underlie sensitivity to these drugs. This could lead
to novel druggable targets that can sensitise tumours to these
agents, with the caveat that combination therapies may increase
toxicity. We demonstrate that ATR is a major determinant of sensi-
tivity to chlorambucil and cisplatin. Most likely, DNA crosslinks
generated by treatment with the two drugs obstruct DNA replica-
tion, and the resulting stalled forks require ATR for their re-start
and stabilisation (Zeman & Cimprich, 2014). Furthermore, consis-
tent with the well-established role of FA in ICL repair, we demon-
strate that FANCD2 inactivation also sensitises cells to either
chlorambucil or cisplatin. As a novel target, we identify SNM1A, a
nuclease with a poorly understood function in ICL repair, as a
factor required for the proliferation of cells treated with chloram-
bucil or cisplatin. Chemical inhibitors against this nuclease may
re-sensitise resistant tumours to chlorambucil and/or cisplatin.
Moreover, our results indicate that SNM1A functions in the context
of the FA pathway of ICL repair, which helps elucidate the cellular
roles of this nuclease.
A second caveat associated with the clinical use of cisplatin is its
well-documented toxicity (Kelland, 2007), mainly in the form of
nephropathies and gastrointestinal tract disorders. The problem was
partially alleviated by the development of new platinum drugs with
lower toxicity, but no benefit for patient survival over cisplatin.
Chlorambucil, which has been part of the standard therapy for CLL
patients for over 50 years either as single agent or in combination
with engineered antibodies (Goede et al, 2013, 2014), shows overall
mild toxicity, occasionally in the form of pancytopenia (Rai et al,
2000).
Consistent with the notion that chlorambucil is less toxic than
cisplatin in patients, our study demonstrates that in vitro and in vivo
chlorambucil treatment triggers lower levels of apoptosis relative to
cisplatin in healthy cells and tissues. We visualised apoptosis in
mice using SPECT in vivo imaging of a radiolabelled apoptosis tracer
and found that it correlates with cH2AX accumulation. IHC staining
showed higher cH2AX levels in the organs of cisplatin-treated mice,
consistent with cisplatin inflicting more DNA lesions than chloram-
bucil. To what extent cisplatin toxicity to healthy tissues can be
attributed to its ability to induce irreversible intrastrand crosslinks
remains to be determined. Importantly, the two drugs were equally
effective in suppressing growth of BRCA2-deficient xenografts.
Given the lower toxicity of chlorambucil relative to cisplatin in mice
and given that the two drugs show comparable anti-tumoral activity
against BRCA-deficient tumours, our results suggest that chlorambu-
cil is a drug with a therapeutic index superior to cisplatin against
the BRCA-deficient tumour subset. In addition, chlorambucil is a
drug administered orally, like the PARP inhibitor olaparib, in
contrast to cisplatin which is an intravenous drug.
One potential caveat associated with administering alkylating
agents, including chlorambucil, to CLL patients is the relatively high
risk of primary tumours at other sites (Maurer et al, 2016). Whilst
concrete evidence for this association was lacking in an initial study
(Hisada et al, 2001), a subsequent evaluation established an
increased (but not significant) incidence of epithelial cancers and
acute myeloid leukaemia in chlorambucil recipients (Grosse et al,
2009). Thus, potential carcinogenic effects of chlorambucil must be
taken into consideration when evaluating chlorambucil and other
agents known to inflict ICLs for clinical use.
Overall the results reported here suggest that the efficacy of chlo-
rambucil assessed in early clinical trials of breast and ovarian cancer
patients was obscured by the lack of molecular markers. Thus,
patient stratification based on BRCA1/2 status may help identify
those tumours vulnerable to chlorambucil. Recent studies have
shown that treatments based on the alkylating agent cyclophos-
phamide are effective in the subset of BRCA1/2-mutated patients
(Vollebergh et al, 2014). Our results corroborate the specificity of
alkylating agents in this setting and suggest that the therapeutic
potential of chlorambucil in BRCA1/2-mutated patients should be
re-evaluated.
Materials and Methods
Cell lines and growth conditions
BRCA2-mutated hamster cells transduced with empty vector or
BRCA2 [V-C8 and V-C8 + BRCA2, respectively (Kraakman-van der
Zwet et al, 2002)], BRCA2+/+ and BRCA2/ human colorectal
adenocarcinoma DLD1 cells (Horizon Discovery; Zimmer et al,
2016), MIA PaCa-2 human pancreatic carcinoma cells and MRC5
human lung fibroblast cells were cultivated in monolayers in DMEM
(Sigma-Aldrich) supplemented with 10% foetal bovine serum (Life
Technologies) and 1% penicillin/streptomycin (Sigma-Aldrich).
Human retinal pigment epithelial cells RPE1, wild type or trans-
duced with hTERT and TP53-deleted (BRCA1+/+ and BRCA1/; a
gift from Dr. Dan Durocher, University of Toronto, Canada; Zimmer-
mann et al, 2018) were cultivated as above in presence of 2 lg/ml
blasticidin (Life Technologies). BRCA2+/+ and BRCA2/ human
colorectal carcinoma HCT116 cells (Ximbio, Cancer Research Tech-
nology) were grown in McCoy’s 5a media (Life Technologies) with
10% foetal bovine serum and 1% penicillin/streptomycin.
Mouse mammary tumour cell lines KP3.33 (Brca1+/+ control),
KB1PM5 (Brca1/, PARP inhibitor sensitive) and KB1PM5
[Brca1/, 53BP1-deficient, PARP inhibitor resistant (Jaspers et al,
2013)] were cultured at 37°C, 5% CO2 and 3% oxygen in complete
medium DMEM/F-12 (Life Technologies) supplemented with 10%
foetal bovine serum (Life Technologies), 1% penicillin/streptomycin
(Sigma-Aldrich), 5 lg/ml insulin (Sigma-Aldrich), 5 ng/ml epider-
mal growth factor (Life Technologies) and 5 ng/ml cholera toxin
(Gentaur).
Human Capan-1 pancreatic carcinoma-derived cells were culti-
vated in IMDM (Life Technologies) with 20% foetal bovine serum,
1% penicillin/streptomycin. Human PEO-1 ovarian cancer cells and
the BRCA2-restored clone C4-2 (Sakai et al, 2009) were grown in
RPMI (Life Technologies) supplemented with 2 mM sodium pyru-
vate and 10% foetal bovine serum (Life Technologies). All cell lines
used in this study are p53-compromised, with the exception of
human MRC5 and human RPE1 wild-type cells used for
Appendix Fig S3B and C. All cell lines were routinely genotyped and
tested for mycoplasma contamination.
Chlorambucil (Abcam), irinotecan hydrochloride (Cambridge
Bioscience Ltd), melphalan (Bio-Techne R&D Systems), cisplatin
(Sigma-Aldrich) and olaparib (Selleckchem) were added to the
media at the concentrations indicated. Cells were arrested in
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mitosis with 0.2 lg/ml KaryoMAX Colcemid (Life Technologies)
for 16 h.
Prestwick chemical library screen setup and statistical analysis
Two independent screens were performed, each in triplicate.
BRCA2-deficient and BRCA2-reconstituted hamster cells, respec-
tively, V-C8 and V-C8 + BRCA2 (Kraakman-van der Zwet et al,
2002), were seeded in 96-well plates. Drugs of the Prestwick Chemi-
cal Library (http://www.prestwickchemical.com/prestwick-chemica
l-library.html) supplied at 10 mM in DMSO were added 24 h later at
5 lM dilution in 100 ll of culture media. Each plate contained
DMSO control wells. Following incubation with the drugs for 3 days
(screen 1) or 6 days (screen 2), viability was assessed using resa-
zurin-based assays.
The library consisted of 16 plates (32 plates were used per cell
line in each screen); therefore, a median plate normalisation proce-
dure was applied, corresponding to a modified version of the robust
per cent of sample (Birmingham et al, 2009). Hits were ranked
using strictly standardised mean deviation (Dataset EV1; Zhang,
2011).
Cell viability assays
Cells were plated at densities varying between 100 and 2,000 cells
per well in 96-well plates. These densities were determined for each
cell line individually, so that they reached 80–90% confluency after
7 days in culture in the absence of any treatment. Drugs were added
at the indicated concentrations on the following day. Six days later,
cell viability was determined by incubating cells with medium
containing 10 lg/ml of resazurin for 2 h. Fluorescence was
measured at 590 nm using a plate reader (POLARstar, Omega). Cell
viability was expressed relative to cells treated with vehicle control
of the same cell line, thus accounting for any differences in viability
caused by genetic modifications.
Spheroid cultures
Ten thousand cells of colorectal adenocarcinoma DLD1 cells were
plated in a well of a 96 round-bottom well, ultra-low attachment
plate (Costar) before being centrifuged at 210 × g for 10 min. Spher-
oids were cultured for 4 days as in published protocols (Friedrich
et al, 2009) before removal of half of the media and addition of the
drugs diluted in that same volume. For untreated control spheroids,
complete media containing the corresponding solvent was added.
For drug-treated spheroids, fresh media containing the drug were
added every 72 h. Pictures of the spheroids were acquired using a
Nikon TE2000-E microscope, and volumes were analysed with
MATLAB R2014a.
Immunoblotting
To prepare whole-cell extracts, cells were washed once in
1× PBS, harvested by trypsinisation, washed in 1× PBS and re-
suspended in SDS–PAGE loading buffer, supplemented with
0.1 mM DTT. Samples were sonicated using a probe sonicator
and heated at 70°C for 10 min. Equal amounts of protein (30–
100 lg) were analysed by gel electrophoresis followed by Western
blotting. NuPAGE-Novex 10% Bis–Tris and NuPAGE-Novex 3–8%
Tris–acetate gels (Life Technologies) were run according to manu-
facturer’s instructions.
siRNA
RPE1 cells were transfected using DharmaFECT-1 (Dharmacon, #T-
2001-03). Briefly, 4 × 105 cells were transfected with 40 nM siRNA
per plate by reverse transfection in 6-cm plates. After 24-h incuba-
tion, depletion was determined by immunoblotting. The ATR siRNA
sequence was CAG GCA CTA ATT GTT CTT CAA. siRNA SMART
pools were used against FANCD2 (Dharmacon, #M-016376-02-
0005), XPF/ERCC4 (Dharmacon, #L-019946-00-0005) and against
SNM1A (Dharmacon, #M-010790-00-0005). AllStars siRNA (Qiagen,
#1027281) was used as a negative control.
Preparation of metaphase chromosome spreads
Cells synchronised in mitosis via overnight incubation with 0.1 lg/ml
KaryoMAX Colcemid (Life Technologies) were collected by mitotic
shake-off and swollen in hypotonic buffer (0.03 M sodium citrate) at
37°C for 25 min. Cells were fixed in freshly prepared 3:1 mix of
methanol: glacial acetic acid, and nuclear preparations were dropped
onto slides pre-soaked in 45% acetic acid prior to being allowed to
dry overnight. The following day, mitotic chromosomes were stained
using Giemsa (VWR) and viewed with a Leica DMI6000B inverted
microscope equipped with a HCX PL APO 100×/1.4–0.7 oil objective.
FACS analysis
BRCA2+/+ and BRCA2/ DLD1 cells treated for 48 h with 1 lM of
cisplatin or 1 lM chlorambucil were incubated with 10 lM EdU for
1 h at 37°C. Cells were harvested by trypsinisation and processed
for EdU staining using the Click-iT Plus Alexa Fluor 647 Flow
Cytometry Assay Kit (Thermo Fisher Scientific). Cells were incu-
bated with 20 lg/ml propidium iodide and 10 lg/ml RNase A
(Sigma) in PBS. At least 10,000 cells were analysed by flow cytome-
try (FACSCalibur, BD Biosciences). Data were processed using
FlowJo (FlowJo, LLC) software.
In vivo xenograft experiments
CB17/SCID male mice (CB17/Icr-Prkdcscid/IcrIcoCrl, 6 weeks old
and weighing 26–28 g) were purchased from Charles River Labora-
tories (Calco, Italy). The mice were maintained in high-efficiency,
particulate air HEPA-filtered racks and were fed autoclaved labora-
tory rodent diet. All animal procedures were in compliance with the
national and international directives (D.L. 4 March 2014, no. 26;
directive 2010/63/EU of the European Parliament and of the coun-
cil; Guide for the Care and Use of Laboratory Animals, United States
National Research Council, 2011).
To generate xenografts derived from HCT116 BRCA2-proficient or
HCT116 BRCA2-deficient cells, CB17/SCID mice were injected intra-
muscularly into the hind leg muscles with 5 × 106 cells per mouse.
When a tumour volume of approximately 250 mm3 was evident in
BRCA2-proficient (4 days after cell injection) and BRCA2-deficient
(6 days after cell injection) xenografts, mice were randomised in
vehicle and treated groups and the treatment was initiated. For
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xenografts derived from DLD1 BRCA2-proficient or DLD1 BRCA2-
deficient cells, tumours were grown subcutaneously until they
reached a mean volume of approximately 100 mm3 (BRCA2-defi-
cient) and 150 mm3 (BRCA2-proficient), at which point the treatment
was initiated. Each experimental group included five mice.
Chlorambucil (3, 1 or 0.3 mg/kg/day) was administered intraperi-
toneally for five consecutive days, followed by 2-day break and 5
more days of treatment. Based on previously established maximum
tolerated dose (Leonetti et al, 1996), cisplatin (3.3 mg/kg/day) was
administered intraperitoneally for three consecutive days, followed
by 4-day break and 3 more days of treatment. Talazoparib (0.33 mg/
kg/day) was administered orally for five consecutive days, followed
by 2-day break and 5 more days of treatment. At the time points indi-
cated, tumour volumes were measured in two dimensions using a
calliper and tumour weight was estimated from tumour volume
(1 mg = 1 mm3). Tumour weight inhibition was calculated using the
formula a × b2/2, where a and b are the long and short sizes of the
tumour, respectively, at the nadir of the effect. The number of mice
used in each experiment is described in each figure legend.
Ex vivo drug experiments
The ex vivo drug treatment protocol was performed as previously
described (Bruna et al, 2016). Briefly, frozen patient-derived
tumour xenografts (PDTXs) were thawed and dissociated on the
GentleMACS Dissociator (Miltenyi Biotec, Cat ID 130-093-235)
using the Tumour Dissociation Kit, human (Miltenyi Biotec, Cat ID
130-095-929) and preset protocol h_tumour_01. Single cells were
plated at ~ 40,000 cells/ml in 96-well plates and dosed 72 h after
plating. Cell Titer Glo 3D was added to the cells 6 days after
dosing. Plates were read on the Pherastar plate reader using the
Luminescence module.
In vivo apoptosis detection
Wild-type Balb/c female mice (6 weeks old and weighing 16–23 g)
were purchased from Charles River (UK). Animals were housed in
individually ventilated cages in sex-matched groups of up to six per
cage in an artificial day–night cycle facility with ad libitum access to
food and water. All analyses were performed blinded to experimen-
tal group assignment.
Mice were injected intraperitoneally with 0.9% saline (n = 5),
3.3 mg/kg/day cisplatin (n = 5) for 3 days or with 3 mg/kg/day
chlorambucil (n = 5) for 5 days. 99mTc-Duramycin was prepared as
previously described (Palmieri et al, 2018). The purity was checked
by RP18 HPLC and confirmed to be over 95%. Mice were injected
intravenously 2 days after the end of treatment with 1 lg of 99mTc-
Duramycin (2–4 MBq) and were imaged 2 h later, using a VECTor
PET/SPECT/CT scanner (MILabs, Utrecht, the Netherlands). After
the final imaging session, mice were euthanised by cervical disloca-
tion and selected organs and tissues were removed. The amount
of radioactivity in each organ was measured using a 1470 WIZARD
gamma counter (PerkinElmer). Counts per minute were converted
into MBq using a calibration curve generated from known
standards. These values were decay-corrected to the time of injec-
tion, and the percentage of the injected dose per gram (% ID/g) of
each organ was calculated. A second cohort of mice (n = 3 per
group) treated with the same protocol were sacrificed for
immunohistochemical staining of selected organs. These animal
procedures were performed in accordance with the UK Animals (Sci-
entific Procedures) Act 1986 and with local ethical committee
approval.
Immunohistochemistry
Tissues collected from experimental mice were fixed in 10% forma-
lin pH 7.4 (VWR Chemicals) for 24 h before dehydrating in 70%
EtOH for 24 h and embedding in paraffin (ThermoScientific,
Histostar and Histoplast paraffin). Formalin-fixed and paraffin-
embedded lungs and hearts were sectioned onto slides (ThermoSci-
entific Superfrost Ultra-Plus) at 3–5 lm thickness. Immunohisto-
chemistry was performed by de-parafinising (two baths of xylene,
for 3 min each), dehydrating (two baths of 100% EtOH, for 3 min
each) and rehydrating the slides (in baths of 95, 90, 70 and 50%
EtOH for 3 min each). Controlled antigen retrieval was induced with
citrate buffer (pH 6.0) for 2 min at 110°C (BioCare Medical, decloak-
ing chamber). Slides were then prepared with Dako EnVision+ Dual
link system, HRP kit dual enzyme endogenous blocking buffer for
15 min. Slides were incubated with primary antibody (rabbit anti-
mouse phosphorylated H2AX Ser139, Abcam ab11174) diluted
1:500 overnight at 4°C. The secondary detection system was Dako
EnVision HRP polymer-labelled rabbit antibodies and DAB was
diluted with the substrate buffer 1:25 and washed of the slides with
water after 2 min of incubation counterstained with haematoxylin
(Sigma-Aldrich) and mounted with coverslips (Sigma-Aldrich DPX
mountant for histology, Menzel-Glaser #1.5 coverslips).
The paper explained
Problem
BRCA1 and BRCA2 are major tumour suppressors. Germline mutations
in these genes are associated with approximately 25% of the familial
cases of breast and ovarian cancer and a significant proportion of
sporadic cancers show BRCA1 and BRCA2 gene inactivation. Thus,
there is a large number of patients affected by BRCA1/2 deficiency.
BRCA1 and BRCA2 proteins play key roles in homologous recombina-
tion repair and their loss triggers high sensitivity to DNA damage.
Drugs that induce DNA lesions are routinely used in the clinic to treat
BRCA1/2-deficient tumours (e.g. cisplatin and PARP inhibitors).
However, most tumours acquire resistance to these therapies and
novel strategies for their elimination are needed.
Results
Here, we report a screen of the Prestwick chemical library of FDA-
approved drugs for compounds that target specifically BRCA2-deficient
cells. We identify chlorambucil as the highest scoring hit from this
screen, which selectively eliminates BRCA1/2-deficient cells and
tumours, including olaparib-resistant and cisplatin-resistant ones.
Importantly, chlorambucil is substantially less toxic to normal cells
and tissues than cisplatin, a drug routinely used in the clinic for
cancer treatment.
Impact
Chlorambucil and cisplatin are equally effective in targeting specifi-
cally BRCA1/2-deficient tumours. However, chlorambucil exhibits lower
toxicity to normal cells. We propose that chlorambucil may provide
an effective alternative to cisplatin for the treatment of this tumour
subset, either as single therapy or in combination with other agents.
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Antibodies
The following antibodies were used for immunoblotting: rabbit
polyclonal antisera raised against phosphorylated KAP1 Ser824
(1:1,000, A300-767A, Bethyl Laboratories), KAP1 (1:5,000, A300-
274A, Bethyl Laboratories), cleaved PARP1 Asp214 (1:1,000, 9541,
Cell Signaling), PARP (1:1,000, 9532, Cell Signalling), ATR (1:2,000,
A300-137A, Bethyl Laboratories), CHD4 (1:200, Active Motif,
39289), phosphorylated RPA Ser33 (1:1,000, A300-246A, Bethyl
Laboratories), SNM1A (1:1,000, A303-747A, Bethyl Laboratories),
FANCD2 (1:2,000, NB100-182, Novus Biologicals) and SMC1
(1:10,000, BL308, Bethyl Laboratories); mouse monoclonal antibod-
ies raised against BRCA2 (1:1,000, OP95, Calbiochem), RPA
(1:1,000, ab2175, Abcam), GAPDH (1:30,000, 6C5, Novus Biologi-
cals) and XPF (1:8,000, MS-1381-P0, Thermo Fisher).
Statistical analysis
Cell line experiments were performed at least three independent
times, with technical triplicates for each condition. Results are
shown as the average of three independent experiments, unless
otherwise indicated, with SEM (standard error of the mean) bars
shown for every datapoint. For two-group comparisons data were
analysed using unpaired t-tests or Mann–Whitney non-parametric
test. One-way ANOVA followed by Tukey’s post hoc test was
performed for multiple comparisons. Differences were considered
statistically significant if P < 0.05.
Expanded View for this article is available online.
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